Pragmatic trials are a transformative approach in clinical research designed to integrate real-world data into clinical trials. They aim to bridge the gap between clinical research and practice by ensuring that trial results are applicable to broader, real-world populations. Here are some key aspects of pragmatic trials:
Real-world applicability: Pragmatic trials are designed to determine whether a therapy works in diverse, real-world settings, addressing a question often unanswered by traditional randomized controlled trials (RCTs) due to their controlled nature and homogeneous populations.
Flexibility: Pragmatic trials offer flexibility by allowing the integration of existing data and the enrollment of diverse populations
Regulatory support: Regulatory frameworks are essential for supporting pragmatic trials, enabling them to transition from controlled research environments to real-world clinical practice. The FDA is actively working to integrate real-world data into clinical trials.
Innovation in design: Pragmatic trials require innovative approaches in clinical trial design to ensure they are efficient and capable of integrating seamlessly into clinical practice.
Operational considerations: Implementing pragmatic trials involves addressing operational challenges, such as accommodating diverse patient populations and settings, selecting the correct sites and patients, and providing tailored training and support for research-naive sites.
The Pressi diagram: Trial designers can use the Pressi diagram to select pragmatic elements to incorporate, such as broadening inclusion criteria or shifting trial settings from academic centers to community clinics.
FDA’s Center for Clinical Trial Innovation (C3TI): The C3TI aims to integrate pragmatic elements into clinical trials through demonstration programs, supporting the broader adoption of innovative trial designs.
